Tyr648

Site Information
DVHNLDyyKKTTNGR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 463337
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 )
Disease tissue studied:	bladder cancer ( 7 ) , gastric cancer ( 2 ) , liver cancer ( 5 , 6 ) , multiple myeloma ( 4 , 8 , 9 , 10 , 11 , 12 , 13 )
Relevant cell line - cell type - tissue:	FU97 (gastric) ( 2 ) , Hep 3B2.1-7 (hepatic) ( 6 ) , HES-3 ('stem, embryonic') ( 1 ) , JHH-7 (hepatic) ( 5 ) , KMS-11 (B lymphocyte) ( 3 , 10 , 11 , 12 ) , NCI-H929 (B lymphocyte) ( 4 ) , OPM-1 (B lymphocyte) ( 8 , 9 , 13 ) , OPM-2 (plasma cell) ( 3 ) , SW780 (bladder cell) ( 7 )

Upstream Regulation
Kinases, in vitro:	FGFR3 (human) ( 14 )
Treatments:	FGF1 ( 3 ) , PD173074 ( 3 )

References
1	Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538 21437283 Curated Info
2	Ren H (2010) CST Curation Set: 9101; Year: 2010; Biosample/Treatment: cell line, FU97/Gleevec; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	St-Germain JR, et al. (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A 106, 20127-32 19901323 Curated Info
4	Possemato A (2009) CST Curation Set: 6933; Year: 2009; Biosample/Treatment: cell line, NCI-H929/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
5	Tucker M (2009) CST Curation Set: 5976; Year: 2009; Biosample/Treatment: cell line, JHH-7/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
6	Tucker M (2009) CST Curation Set: 5947; Year: 2009; Biosample/Treatment: cell line, Hep3B/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Rikova K (2006) CST Curation Set: 2103; Year: 2006; Biosample/Treatment: cell line, SW780/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
8	Gu T (2006) CST Curation Set: 1725; Year: 2006; Biosample/Treatment: cell line, OPM-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Gu T (2006) CST Curation Set: 1726; Year: 2006; Biosample/Treatment: cell line, OPM-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
10	Gu T (2006) CST Curation Set: 1727; Year: 2006; Biosample/Treatment: cell line, KMS-11/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
11	Gu T (2006) CST Curation Set: 1728; Year: 2006; Biosample/Treatment: cell line, KMS-11/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Gu T (2005) CST Curation Set: 875; Year: 2005; Biosample/Treatment: cell line, KMS-11/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Gu T (2005) CST Curation Set: 876; Year: 2005; Biosample/Treatment: cell line, OPM-1/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
14	Webster MK, D'Avis PY, Robertson SC, Donoghue DJ (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16, 4081-7 8754806 Curated Info